Loading...

Loading...

Adjust height of sidebar

KMap

People

Adjust height of sidebar

KMap

Profile

Picture of Jaron Solsky

Jaron Solsky

Manager, Activation

Cancer Center Division

Collaboration(19)

Rachna Shroff
Hina Arif Tiwari
Yana Zavros
Michele Chu-Pilli
Gregory Woodhead

Page 1 of 4

Grants(11)

A Phase 3, Randomized, Open-label Study of MK-5684 versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed O
Active·2024·$0 / $2.2M·
External
prostate cancer, clinical trial, treatment comparison, metastatic cancer, hormone therapy
A Phase 1b, Open-Label, Safety, Tolerability, and Efficacy Study of HC-7366 in Combination with Belzutifan (WELIREG) in Patients with Locally Advanced (Inoperable) or Metastatic Renal Cell Carcinoma
Active·2024·$0 / $625.4K·
External
oncology, clinical trial, drug combination, efficacy, patient safety
A Phase 2, Randomized, Open-label Study of Onvansertib in Combination with FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-line Tre
Active·2024·$0 / $548.6K·
External
oncology, clinical trials, chemotherapy, cancer treatment, targeted therapy
A Phase III Multi-center, Open-label, Sponsor-blinded, Randomized Study of AZD0901 Monotherapy Compared with Investigator's Choice of Therapy in Second- or Later-Line Adult Participants with Advanced/
Active·2024·$0 / $434.6K·
External
clinical trials, cancer treatment, monotherapy
A Phase 2a, Double-Blind, Placebo-Controlled, Multi-Center, Randomized Study Evaluating LSTA1 when Added to Standard of Care (SOC) Versus Standard of Care Alone in Subjects with Advanced Solid Tumors
Active·2023·$0 / $825.5K·
External
oncology, clinical trials, immunotherapy, cancer treatment, drug efficacy

Page 1 of 3